■nectin粘附分子CD112是肿瘤进展的重要组成部分,属于Nectin家族.然而,对其在各种癌症中的临床相关性和机制的综合评估尚待进行。
■这项研究全面检查了预后与CD112表达之间的关系。我们通过使用癌症基因组图谱(TCGA)和基因型组织表达(GTEx)数据库阐明了CD112在肿瘤免疫中的功能。这涉及检查其与肿瘤突变负荷(TMB)的联系,DNA甲基化,肿瘤免疫侵袭,失配修复(MMR),微卫星不稳定性(MSI),和常见的免疫检查点抑制剂(ICIs)。此外,在结直肠癌(CRC)细胞系中检测了CD112敲低对细胞功能的影响.
■在当前的研究中,我们发现恶性组织表达高水平的CD112,这与TMB有关,MMR,MSI,和DNA甲基化。生存分析表明,CD112高表达的患者预后不良的频率更高。此外,CD112表达与CD4阳性(CD4+)T细胞浸润水平呈负相关,CD8阳性(CD8+)T细胞,和T细胞。Western印迹和途径富集分析显示CD112与上皮-间质转化(EMT)显著相关。此外,当CD112被敲低时,CRC细胞迁移和增殖较少。发现CD112表达与患者的抗程序性细胞死亡蛋白1(PD-1)和抗细胞毒性T淋巴细胞相关蛋白4(CTLA-4)治疗结果呈负相关。
■CD112可作为免疫治疗中可能的预后标志物,并可通过上调EMT途径刺激肿瘤生长。
UNASSIGNED: The nectin adhesion molecule CD112, an important component of tumor progression, belongs to the nectin family. However, a comprehensive evaluation of its clinical relevance and mechanism in various cancers is yet to be conducted.
UNASSIGNED: This investigation fully examined the relationship between prognosis and CD112 expression. We clarified the function of CD112 in tumor immunity by employing The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases. This involved examining its connections to tumor mutation burden (TMB), DNA methylation, tumor immune invasion, mismatch repair (MMR), microsatellite instability (MSI), and common immune checkpoint inhibitors (ICIs). Additionally, the impact of CD112 knockdown on cell function was examined in colorectal cancer (CRC) cell lines.
UNASSIGNED: In the current study, we found malignant tissues express high levels of CD112, which was related to TMB, MMR, MSI, and DNA methylation. Survival analysis indicated that patients with high CD112 expression had an unfavorable prognosis more frequently. In addition, CD112 expression was negatively associated with infiltration levels of CD4 positive (CD4+) T cells, CD8 positive (CD8+) T cells, and T cells. Western blotting and pathway enrichment analysis showed that CD112 is significantly linked to epithelial-to-mesenchymal transition (EMT). Additionally, CRC cells migrate and proliferate less when CD112 was knocked down. CD112 expression was found to be negatively associated with anti-programmed cell death protein 1 (PD-1) and anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) treatment outcomes in patients.
UNASSIGNED: CD112 may act as a possible prognostic marker in immune therapy and may stimulate tumor growth by upregulating the EMT pathway.